These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37821306)

  • 21. PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
    Qin Y; Luan J; Zhou X; Li Y
    Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33704390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Genomic Landscape of Vulvar Squamous Cell Carcinoma.
    Corey L; Wallbillich JJ; Wu S; Farrell A; Hodges K; Xiu J; Nabhan C; Guastella A; Kheil M; Gogoi R; Winer I; Bandyopadhyay S; Huang M; Jones N; Wilhite A; Karnezis A; Thaker P; Herzog TJ; Oberley M; Korn WM; Vezina A; Morris R; Ali-Fehmi R
    Int J Gynecol Pathol; 2023 Sep; 42(5):515-522. PubMed ID: 37131274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.
    Huang RSP; Haberberger J; Severson E; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Williams E; Elvin J; Vergilio JA; Killian JK; Lin DI; Tse J; Hiemenz M; Owens C; Danziger N; Hegde PS; Venstrom J; Alexander B; Ross JS; Ramkissoon SH
    Mod Pathol; 2021 Feb; 34(2):252-263. PubMed ID: 32884129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
    Voutsadakis IA
    Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
    [No Abstract]   [Full Text] [Related]  

  • 25. Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation status.
    Zhu X; Jamshed S; Zou J; Azar A; Meng X; Bathini V; Dresser K; Strock C; Yalamarti B; Yang M; Tomaszewicz K; Tjionas G; Mochel MC; Hutchinson L; Bledsoe JR
    Mod Pathol; 2021 May; 34(5):1017-1030. PubMed ID: 33483624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.
    Eich ML; Rodriguez Pena MDC; Springer SU; Taheri D; Tregnago AC; Salles DC; Bezerra SM; Cunha IW; Fujita K; Ertoy D; Bivalacqua TJ; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Netto GJ
    Mod Pathol; 2019 Oct; 32(10):1544-1550. PubMed ID: 31028363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma.
    Salama AM; Momeni-Boroujeni A; Vanderbilt C; Ladanyi M; Soslow R
    Mod Pathol; 2022 Feb; 35(2):274-282. PubMed ID: 34650187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
    Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
    Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic Alterations in Human Papillomavirus-Positive and -Negative Conjunctival Squamous Cell Carcinomas.
    Ramberg I; Vieira FG; Toft PB; von Buchwald C; Funding M; Nielsen FC; Heegaard S
    Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):11. PubMed ID: 34779821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma.
    Alexander RE; Hu Y; Kum JB; Montironi R; Lopez-Beltran A; Maclennan GT; Idrees MT; Emerson RE; Ulbright TM; Grignon DG; Eble JN; Cheng L
    Mod Pathol; 2012 Nov; 25(11):1526-33. PubMed ID: 22684221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High tumour mutational burden is associated with strong PD-L1 expression, HPV negativity, and worse survival in penile squamous cell carcinoma: an analysis of 165 cases.
    Hrudka J; Hojný J; Prouzová Z; Kendall Bártů M; Čapka D; Zavillová N; Matěj R; Waldauf P
    Pathology; 2024 Apr; 56(3):357-366. PubMed ID: 38161143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative molecular profiling of HPV-induced squamous cell carcinomas.
    Koncar RF; Feldman R; Bahassi EM; Hashemi Sadraei N
    Cancer Med; 2017 Jul; 6(7):1673-1685. PubMed ID: 28556593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
    Isharwal S; Hu W; Sarungbam J; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Jadallah S; Loo FL; Pietzak EJ; Cha EK; Bochner BH; Berger MF; Iyer G; Solit DB; Reuter VE; Al-Ahmadie H
    J Pathol; 2019 Jul; 248(3):260-265. PubMed ID: 30838648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma.
    Huang RSP; Haberberger J; Murugesan K; Danziger N; Hiemenz M; Severson E; Duncan DL; Ramkissoon SH; Ross JS; Elvin JA; Lin DI
    Mod Pathol; 2021 Jul; 34(7):1425-1433. PubMed ID: 33637877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
    Huang RSP; Li X; Haberberger J; Sokol E; Severson E; Duncan DL; Hemmerich A; Edgerly C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Hiemenz M; Xiao J; McEwan D; Holmes O; Danziger N; Erlich R; Frampton G; Cohen MB; McGregor K; Reddy P; Cardeiro D; Anhorn R; Venstrom J; Alexander B; Brown C; Pusztai L; Ross JS; Ramkissoon SH
    Oncologist; 2020 Nov; 25(11):943-953. PubMed ID: 32869930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study.
    Ma YT; Hua F; Zhong XM; Xue YJ; Li J; Nie YC; Zhang XD; Ma JW; Lin CH; Zhang HZ; He W; Sha D; Zhao MQ; Yao ZG
    Front Immunol; 2023; 14():1269097. PubMed ID: 38022513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.
    Chung CH; Guthrie VB; Masica DL; Tokheim C; Kang H; Richmon J; Agrawal N; Fakhry C; Quon H; Subramaniam RM; Zuo Z; Seiwert T; Chalmers ZR; Frampton GM; Ali SM; Yelensky R; Stephens PJ; Miller VA; Karchin R; Bishop JA
    Ann Oncol; 2015 Jun; 26(6):1216-1223. PubMed ID: 25712460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
    Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
    Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
    Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
    J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.